Modulation of bcl-xL in tumor cells regulates angiogenesis through CXCL8 expression

Molecular Cancer Research

Volumn 5, Issue 8, 2007, Pages 761-771

  Giorgini, Simona ^a   Trisciuoglio, Daniela ^a   Gabellini, Chiara ^a   Desideri, Marianna ^a   Castellini, Laura ^a   Colarossi, Cristina ^b   Zangemeister Wittke, Uwe ^c   Zupi, Gabriella ^a   Del Bufalo, Donatella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; INTERLEUKIN 8; MATRIGEL; MESSENGER RNA; NEUTRALIZING ANTIBODY; PROTEIN BCL XL;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CLONING; COLON CARCINOMA; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; MELANOMA; MORPHOGENESIS; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; TUMOR CELL; TUMOR CELL LINE; VALIDATION PROCESS;

BCL-X PROTEIN; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELLS, CULTURED; COLLAGEN; DRUG COMBINATIONS; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INTERLEUKIN-8; LAMININ; MELANOMA, EXPERIMENTAL; NEOVASCULARIZATION, PATHOLOGIC; OLIGONUCLEOTIDES, ANTISENSE; PROMOTER REGIONS (GENETICS); PROTEIN ARRAY ANALYSIS; PROTEOGLYCANS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; UMBILICAL VEINS;

EID: 34548092663     PISSN: 15417786     EISSN: None     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-07-0088     Document Type: Article

References (42)

1. Folkman J, Watson K, Ingber D, Hanahan D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989;339:58-61.
2. Mukhopadhyay D, Tsiokas L, Zhou, XM, Foster D, Brugge JS, Sukhatme VP. Hypoxic induction of human vascular endothelial growth factor expression through c-Src activation. Nature 1995;375:577-81.
3. Del Bufalo D, Biroccio A, Leonetti C, Zupi G. Bcl-2 overexpression enhances the metastatic potential of a human breast cancer line. FASEB J 1997;11:947-53.
4. Biroccio A, Candiloro A, Mottolese M, et al. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J 2000;14:652-60.
5. Iervolino A, Trisciuoglio D, Ribatti D, et al. Bcl-2 overexpression in human melanoma cells increases angiogenesis through VEGF mRNA stabilization and HIF-1-mediated transcriptional activity. FASEB J 2002;16:1453-5.
6. Trisciuoglio D, Desideri M, Ciuffreda L, et al. Bcl-2 overexpression in melanoma cells increases tumor progression-associated properties and in vivo tumor growth. J Cell Physiol 2005;205:414-21.
7. Trisciuoglio D, Iervolino A, Zupi G, Del Bufalo D. Involvement of PI3K and MAPK signaling in bcl-2-induced vascular endothelial growth factor expression in melanoma cells. Mol Biol Cell 2005;16:4153-62.
8. Del Bufalo D, Trisciuoglio D, Scarsella M, Zangemeister-Wittke U, Zupi G. Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene 2003;22:8441-7.
9. Fernandez A, Udagawa T, Schwesinger C, et al. Angiogenic potential of prostate carcinoma cells overexpressing bcl-2. J Natl Cancer Inst 2001;93:208-13.
10. Karl E, Warner K, Zeitlin B, et al. Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-κB and CXC chemokines. Cancer Res 2005;65:5063-9.
11. Zhu H, Guo W, Zhang L, et al. Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther 2005;4:451-6.
12. Itoh T, Itoh A, Pleasure D. Bcl-2-related protein family gene expression during oligodendroglial differentiation. J Neurochem 2003;85:1500-12.
13. Wakabayashi K, Saito H, Ebinuma H, et al. Bcl-2 related proteins are dramatically induced at the early stage of differentiation in human liver cancer cells by a histone deacetylase inhibitor projecting an antiapoptotic role during this period. Oncol Rep 2000;7:285-8.
14. Lakics V, Medvedev AE, Okada S, Vogel SN. Inhibition of LPS-induced cytokines by Bcl-xL in a murine macrophage cell line. J Immunol 2000;165:2729-37.
15. Martin SS, Ridgeway AG, Pinkas J, et al. A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene 2004;23:4641-5.
16. Coluccia AM, Perego S, Cleris L, et al. Bcl-xL down-regulation suppresses the tumorigenic potential of NPM/ALK in vitro and in vivo. Blood 2004;103:2787-94.
17. Brat DJ, Castellano-Sanchez A, Kaur B, Van Meir EG. Genetic and biologic progression in astrocytomas and their relation to angiogenic dysregulation. Adv Anat Pathol 2002;91:24-36.
18. Jiang Z, Zheng X, Rich KM. Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death. J Neurochem 2003;84:273-81.
19. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ. Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3 - like proteases. Proc Natl Acad Sci U S A 1998;95:5724-9.
20. Weiler M, Bahr O, Hohlweg U, et al. BCL-xL: time-dependent dissociation between modulation of apoptosis and invasiveness in human malignant glioma cells. Cell Death Differ 2006;13:1156-69.
21. Krajewski S, Krajewska M, Ehrmann J, et al. Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am J Pathol 1997;150:805-14.
22. Martin S, Toquet C, Oliver L, et al. Expression of bcl-2, bax and bcl-xL in human gliomas: a re-appraisal. J Neurooncol 2001;52:129-39.
23. Olie RA, Hafner C, Kuttel R, et al. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J Invest Dermatol 2002;118:505-12.
24. Leiter U, Schmid RM, Kaskel P, Peter RU, Krahn G. Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 2000;292:225-32.
25. Bush JA, Li G. The role of Bcl-2 family members in the progression of cutaneous melanoma. Clin Exp Metastasis 2003;20:531-9.
26. Zhang H, Rosdahl I. Bcl-xL and bcl-2 proteins in melanoma progression and UVB-induced apoptosis. Int J Oncol 2006;28:661-6.
27. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992;258:1798-801.
28. Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol 2003;170:3369-76.
29. Mukaida N, Mahe Y, Matsushima K. Cooperative interaction of nuclear factor-κB and cis-regulatory enhancer binding protein-like factor binding elements in activating the interleukin-8 gene by pro-inflammatory cytokines. J Biol Chem 1990;265:21128-33.
30. Castilla C, Congregado B, Chinchon D, et al. Bcl-xL is overexpressed in hormone-resistant prostate cancer and promotes survival of LNCaP cells via interaction with proapoptotic Bak. Endocrinology 2006;147:4960-7.
31. Sulkowski S, Kanczuga-Koda L, Koda M, et al. M Insulin-like growth factor-I receptor correlates with connexin 26 and Bcl-xL expression in human colorectal cancer. Ann N Y Acad Sci 2006;1090:265-75.
32. Del Bufalo D, Trisciuoglio D, Scarsella M, Zangemeister-Wittke U, Zupi G. Lonidamine causes inhibition of angiogenesis-related endothelial cell functions. Neoplasia 2004;6:513-22.
33. Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro-oncol 2005;7:122-33.
34. Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004;6:447-58.
35. Garkavtsev I, Kozin SV, Chernova O, et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004;428:328-32.
36. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001;19:577-83.
37. Varney ML, Johansson SL, Singh RK. Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol 2006;125:209-16.
38. Nurnberg W, Tobias D, Otto F, Henz BM, Schadendorf D. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol 1999;189:546-51.
39. Reed JC. Dysregulation of apoptosis in cancer. J Clin Oncol 1999;17:2941-53.
40. Kim SH, Nakagawa H, Navaraj A, et al. Tumorigenic conversion of primary human esophageal epithelial cells using oncogene combinations in the absence of exogenous Ras. Cancer Res 2006;66:10415-24.
41. Zangemeister-Wittke U, Leech SH, Olie RA, et al. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells. Clin Cancer Res 2000;6:2547-55.
42. Holtmann H, Winzen R, Holland P, et al. Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways. Mol Cell Biol 1999;19:6742-53.